Loading clinical trials...
Loading clinical trials...
Relationship Between Patient Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease.
The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.
Our intentions are to phenotype Chronic Obstructive Pulmonary Disease (COPD) patients on the basis of factors that a related to (a) exacerbation frequency which will include (b) lung function to assess disease severity, (c) baseline therapy, (d) airway and systemic inflammatory markers, (e) health status, (f) gene expression, (g) airway bacterial and viral load and (h) co-morbidity including cardiovascular disease, diabetes and psychological disease, (i) psychological factors,(j) mortality, (k) nasal susceptibility to rhinovirus infection, (l) heart rate variability (m) exhaled hydrogen sulphide.
Age
40 - 100 years
Sex
ALL
Healthy Volunteers
No
National Heart and Lung Institute, Imperial College
London, United Kingdom
Start Date
January 1, 2009
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
June 21, 2022
300
ESTIMATED participants
Lead Sponsor
Imperial College London
NCT06831994
NCT05050591
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05913765